NCT05579691View on ClinicalTrials.gov

A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 21, 2022

Primary Completion Date

December 4, 2023

Study Completion Date

December 4, 2023

Conditions
Friedreich Ataxia
Interventions
BIOLOGICAL

CTI-1601

CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia

OTHER

Placebo

Placebo Comparator

Trial Locations (1)

07724

Clinilabs Drug Development Corporation, Eatontown

Sponsors
All Listed Sponsors
lead

Larimar Therapeutics, Inc.

INDUSTRY